Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay

Published: Wednesday, November 28, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil’s healthcare system.

Trovagene, Inc. and the PIO XII Foundation, affiliated with Brazil’s Barretos Cancer Hospital, today announced that they entered into a research collaboration to evaluate the performance of a urine-based molecular assay for detection of HPV types associated with cervical lesions. The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil’s healthcare system. Barretos Cancer Hospital, Brazil’s preeminent center for oncology research and cancer treatment, will conduct the study using Trovagene’s proprietary, urine-based method for determining the presence of high risk HPV types, allowing for completely non-invasive HPV carrier screening.
HPV infections are the leading cause of cervical cancer. In medically underserved regions, traditional screening methods to detect elevated risk of cervical cancer, such as a Pap smear, are not broadly available. In Brazil, cervical cancer is the second most frequent tumor type in women and the leading cause of cancer-related mortality in women 14 to 44 years of age. Brazil has placed special emphasis on programs to improve HPV screening to address this pressing healthcare need.
"We are excited to begin this important clinical trial using Trovagene’s proprietary urine-based HPV assay," says Adhemar Longatto Filho, M.Sc., Ph.D., PMIAC, from the Laboratory of Medical Investigation at the University of Sao Paulo and principal investigator for the study at Barretos Cancer Hospital. "This study can pave the way to make HPV screening broadly available to medically underserved patients in our region. Our goal is to provide patients with non-invasive testing options to determine their HPV risk factor and significantly improve women’s healthcare in Brazil."
"We are committed to work with Barretos Cancer Hospital to study the performance of our proprietary HPV assay in Brazil. Improved logistics, reduced costs and increased compliance can significantly increase HPV screening rates and save lives," states Antonius Schuh, Ph.D., chief executive officer of Trovagene. “This collaboration with Barretos is another important step towards making Trovagene’s non-invasive HPV carrier screen available in key healthcare markets globally.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Mr. Zaniboni's experience includes raising more than $500 million through venture financing and IPO proceeds.
Friday, February 10, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos